Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 18, 2009, Pages 7385-7390

  Klein, Joshua S ^a   Gnanapragasam, Priyanthi N P ^b   Galimidi, Rachel P ^b   Foglesong, Christopher P ^b   West Jr , Anthony P ^b   Bjorkman, Pamela J ^b  

^a Graduate Option in Biochemistry and Molecular Biophysics   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN GP41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; CROSS LINKING; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; SPIKE; VIRION; CHEMISTRY; HUMAN; IMMUNOLOGY; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NEUTRALIZATION TESTS;

EID: 66149132686     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811427106     Document Type: Article

References (55)

1. WeiX, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422:307-312.
2. Kwong PD, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
3. Labrijn AF, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120isstericallyrestricted on primaryhuman immunodeficiency virus type 1. J Virol 77:10557-10565.
4. Chen B, et al. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
5. Kwong PD, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
6. Burton DR, Stanfield RL, Wilson IA (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102:14943-14948.
7. Burton DR, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
8. BarbasCF,III, etal. (1992)Recombinanthuman Fab fragmentsneutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 89:9339-9343.
9. Zwick MB, et al. (2001) Broadly neutralizing antibodies targeted to the membrane- proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905.
10. Cardoso RM, et al. (2007) Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 365:1533-1544.
11. BuchacherAR, etal. (1992)Human monoclonal antibodiesagainstgp41 and gp120as potential agent for passive immunization. Vaccines 92:191-195.
12. Muster T, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642-6647.
13. Binley JM, etal. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78:13232-13252.
14. Wu H, et al. (2005) Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350:126-144.
15. Icenogle J, etal. (1983) Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry. Virology 127:412-425.
16. Cavacini LA, Emes CL, Power J, Duval M, Posner MR (1994) Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. J immunol 152:2538 -2545.
17. Zhu Z, et al. (2006) Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. JVirol 80:891-899.
18. KausmallyL, etal. (2004) Neutralizing human antibodies to varicella-zoster virus(VZV) derived from a VZV patient recombinant antibody library. J Gen Virol 85:3493-3500.
19. Janeway CA, Travers P, Walport M, Schlomchik MJ (2005) Immunobiology (Garland Science Publishing, New York), 6th Ed.
20. Liu J, Bartesaghi A, Borgnia MJ, SapiroG,Subramaniam S(2008)Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113.
21. Zhu P, etal. (2006) Distribution and three-dimensional structure ofAIDS virusenvelope spikes. Nature 441:847-852.
22. Sougrat R, et al. (2007) Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 3:e63.
23. Chertova E, etal. (2002) Envelope glycoprotein incorporation, notshedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76:5315-5325.
24. Yamaguchi M, Danev R, Nishiyama K, Sugawara K, Nagayama K (2008) Zernike phase contrast electron microscopy of ice-embedded influenza A virus. J Struct Biol 162:271-276.
25. Bird RE, et al. (1988) Single-chain antigen-binding proteins. Science 242:423-426.
26. Huston JS, et al. (1988) Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879-5883.
27. Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021-7025.
28. Bennett MJ, Eisenberg D (2004) The evolving role of 3D domain swapping in proteins. Structure (London) 12:1339-1341.
29. Holliger P, Prospero T, Winter G (1993) "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448.
30. Perisic O, Webb PA, Holliger P, Winter G, Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure (London) 2:1217-1226.
31. Brunel FM, et al. (2006) Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 80:1680-1687.
32. Li M, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and earlysubtypeB infectionsfor standardized assessmentsofvaccine-elicited neutralizing antibodies. J Virol 79:10108-10125.
33. Sun ZY, et al. (2008) HIV-1 Broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63.
34. Cardoso RM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. immunity 22:163-173.
35. Schofield DJ, Stephenson JR, Dimmock NJ (1997) Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGsand their antibody fragments. JGen Virol 78 (Pt 10):2431-2439.
36. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H (2004) Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIVtype 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 20:755-762.
37. Frey G, et al. (2008) A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 105:3739-3744.
38. Gustchina E, Bewley CA, Clore GM (2008) Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodiesdirected againstthe N-terminal helical repeat of gp41. J Virol 82:10032-10041.
39. LawM, Cardoso RM, Wilson IA, Burton DR (2007) Antigenic and immunogenic studyof membrane-proximal external region-grafted gp120 antigens bya DNA prime-protein boost immunization strategy. JVirol 81:4272-4285.
40. Zwick MB (2005) The membrane-proximal external region of HIV-1 gp41: A vaccine target worth exploring. AIDS 19:1725-1737.
41. Muster T, et al. (1994) Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68:4031-4034.
42. McGaughey GB, et al. (2003) HIV-1 vaccine development: Constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry42:3214-3223.
43. Liang X, et al. (1999) Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 17:2862-2872.
44. Joyce JG, et al. (2002) Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. implications for vaccine design. J Biol Chem 277:45811-45820.
45. Ho J, et al. (2005) Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 23:1559-1573.
46. Eckhart L, et al. (1996) immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol 77 (Pt 9):2001-2008.
47. Phogat S, et al. (2008) Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology373:72-84.
48. Fagerstam LG, Frostell-Karlsson A, Karlsson R, Persson B, Ronnberg i (1992) Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. JChromatogr597:397-410.
49. Malmqvist M (1993) Biospecific interaction analysis using biosensor technology. Nature 361:186-187.
50. Myszka DG (1999) improving biosensor analysis. J Mol Recognit 12:279-284.
51. Myszka DG, Morton TA (1998) CLAMP: A biosensor kinetic data analysis program. Trends Biochem Sci 23:149-150.
52. Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patientsreceiving fusion inhibitor (T-20)monotherapy. AntimicrobAgentsChemother 46:1896-1905.
53. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18:2714-2723.
54. DeLanoWL(2008) The PyMOL Molecular Graphics System (DeLano Scientific, Palo Alto, CA).
55. Saphire EO, et al. (2001) Crystal structure of a neutralizing human iGG against HIV-1: A template for vaccine design. Science 293:1155-1159.